Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn study sought to predict who benefits from obesity drug combo

NCT ID NCT06619015

Knowledge-focused Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aimed to see if adding pramlintide to semaglutide (Wegovy) could change appetite and eating habits in obese people with prediabetes. It also tried to find ways to predict who would respond best to obesity medication. The trial was withdrawn before any participants were enrolled, so no results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pramlintide and semaglutide
What this could lead to
If it had succeeded, this study could have pointed toward more personalized obesity treatments by identifying who responds best to certain drug combinations.
What could go wrong
The study was withdrawn before enrolling anyone, so no results are available. Even if conducted, it was small (40 people) and only lasted 26 weeks, making it too early to draw broad conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Started

Apr 2025

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≧ 30kg/m2 * HbA1c 39-47 mmol/mol (pre-diabetes) * Male or female * Aged \>18 years of age and \<70 years * Negative pregnancy test, and willing to use contraceptives during the study period Exclusion Criteria: * Presence of diabetes with or without treatment * Current or recent (\<6 months) treatment with GLP1 RA's * Previous gastrointestinal surgery that might affect gastric emptying, nutritional absorption and postprandial GI peptide production * History of acute or chronic pancreatitis * Chronic kidney disease * Use of any antipsychotic drugs * Use of any antiresorptive or bone-anabolic drugs or fractures within \< 6 months * Use of systemic oral glucocorticoids within \< 6 months * Newly (\< 3 months) initiated hormonal contraceptive or other hormone therapy * Recent (\<3 months) weight loss ≧ 1% of body weight * Presence of Binge eating disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Appetite regulation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Appetite regulation Obesity Prediabetes

Contacts and locations

Locations

  • University hospital of Southern Denmark

    Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.